FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W79901769> ?p ?o ?g. }

• W79901769 endingPage "790" @default.
• W79901769 startingPage "783" @default.
• W79901769 abstract "Biological therapies, such as etanercept, adalimumab and infliximab, have demonstrated good efficacy in inducing rheumatoid arthritis to low disease activity levels. Nevertheless, their cost, as well as the related risk of side effects, especially in long-term therapies, are still high. Furthermore, there is a good deal of evidence proving loss of efficacy of such therapies in the long term, often necessitating the shift from one specific anti-TNF biological treatment to another. There are also other open debates on the amount of time a patient should undergo an anti-TNF therapy, on the possibility of inducing a complete remission in early arthritis and, once remission or low disease activity is obtained, on the possibility of interrupting the anti-TNF-based therapy. In this study we investigated whether A-Cyclosporin and Methotrexate association may be effective in maintaining low disease activity obtained by anti-TNF therapies. Twenty-three rheumatoid arthritis-affected patients, whose diagnosis was made according to ACR criteria, with a disease duration of less than 3 years, and DAS28<3.2 that reached a level of low disease activity within 6–8 months from beginning anti-TNF and Methotrexate therapy, were enrolled in the study. After the suspension of anti-TNF therapy, patients were started on A-Cyclosporine (2–3 mg/kg/day) and Methotrexate (15mg/week) therapy. DAS28, Pain VAS, Erythrosedimentation Rate (ESR), and C Reactive Protein (CRP) were all tested at time 0 and at 6 months, as well as liver and kidney profiles, after the interruption of the anti-TNF therapy and the beginning of A-Cyclosporine and Methotrexate therapy. Side effects were also recorded. Of 23 patients undergoing the A-Cyclosporin and Methotrexate therapy for maintaining low disease activity in rheumatoid arthritis obtained by 6–8 months of anti-TNF therapy, 21 completed the study with a 6 month follow-up. Thirteen patients maintained clinical parameters within low disease activity values, while 8 patients showed an increase in DAS28 and other parameters. Only two patients showed an increase in blood pressure that was diagnosed after two months from the beginning of the A-Cyclosporin and Methotrexate therapy. The reduction in the dosage of A-Cyclosporin from 3mg/kg/day to 2mg/kg/day caused a slow normalization of blood pressure values. Our data seem to suggest that more than half of the patients undergoing A-Cyclosporin and Methotrexate therapy seemed to maintain low disease activity parameters of rheumatoid arthritis, obtained after 6–8 months of anti-TNF therapy. Further studies on larger populations are necessary in order to confirm such results and identify predictor factors for different responses." @default.
• W79901769 created "2016-06-24" @default.
• W79901769 creator A5000691915 @default.
• W79901769 creator A5027026137 @default.
• W79901769 creator A5030773182 @default.
• W79901769 creator A5036746815 @default.
• W79901769 creator A5039581967 @default.
• W79901769 creator A5080570898 @default.
• W79901769 creator A5082483711 @default.
• W79901769 creator A5086236783 @default.
• W79901769 creator A5088965502 @default.
• W79901769 date "2010-07-01" @default.
• W79901769 modified "2023-09-26" @default.
• W79901769 title "Can Cyclosporine-A Associated to Methotrexate Maintain Remission Induced by Anti-TNF Agents in Rheumatoid Arthritis Patients? (Cynar Pilot Study)" @default.
• W79901769 cites W1974236161 @default.
• W79901769 cites W1980354124 @default.
• W79901769 cites W1981383482 @default.
• W79901769 cites W1996472975 @default.
• W79901769 cites W2000905503 @default.
• W79901769 cites W2093828367 @default.
• W79901769 cites W2103310388 @default.
• W79901769 cites W2109745545 @default.
• W79901769 cites W2110177517 @default.
• W79901769 cites W2112966993 @default.
• W79901769 cites W2122265491 @default.
• W79901769 cites W2125346357 @default.
• W79901769 cites W2150622301 @default.
• W79901769 cites W2152553239 @default.
• W79901769 cites W2162254515 @default.
• W79901769 cites W2163204760 @default.
• W79901769 doi "https://doi.org/10.1177/039463201002300312" @default.
• W79901769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20943048" @default.
• W79901769 hasPublicationYear "2010" @default.
• W79901769 type Work @default.
• W79901769 sameAs 79901769 @default.
• W79901769 citedByCount "5" @default.
• W79901769 countsByYear W799017692014 @default.
• W79901769 countsByYear W799017692015 @default.
• W79901769 crossrefType "journal-article" @default.
• W79901769 hasAuthorship W79901769A5000691915 @default.
• W79901769 hasAuthorship W79901769A5027026137 @default.
• W79901769 hasAuthorship W79901769A5030773182 @default.
• W79901769 hasAuthorship W79901769A5036746815 @default.
• W79901769 hasAuthorship W79901769A5039581967 @default.
• W79901769 hasAuthorship W79901769A5080570898 @default.
• W79901769 hasAuthorship W79901769A5082483711 @default.
• W79901769 hasAuthorship W79901769A5086236783 @default.
• W79901769 hasAuthorship W79901769A5088965502 @default.
• W79901769 hasConcept C126322002 @default.
• W79901769 hasConcept C141071460 @default.
• W79901769 hasConcept C17991360 @default.
• W79901769 hasConcept C198451711 @default.
• W79901769 hasConcept C2777077863 @default.
• W79901769 hasConcept C2777138892 @default.
• W79901769 hasConcept C2777226972 @default.
• W79901769 hasConcept C2777575956 @default.
• W79901769 hasConcept C2779722408 @default.
• W79901769 hasConcept C2780132546 @default.
• W79901769 hasConcept C2781059491 @default.
• W79901769 hasConcept C71924100 @default.
• W79901769 hasConcept C90924648 @default.
• W79901769 hasConceptScore W79901769C126322002 @default.
• W79901769 hasConceptScore W79901769C141071460 @default.
• W79901769 hasConceptScore W79901769C17991360 @default.
• W79901769 hasConceptScore W79901769C198451711 @default.
• W79901769 hasConceptScore W79901769C2777077863 @default.
• W79901769 hasConceptScore W79901769C2777138892 @default.
• W79901769 hasConceptScore W79901769C2777226972 @default.
• W79901769 hasConceptScore W79901769C2777575956 @default.
• W79901769 hasConceptScore W79901769C2779722408 @default.
• W79901769 hasConceptScore W79901769C2780132546 @default.
• W79901769 hasConceptScore W79901769C2781059491 @default.
• W79901769 hasConceptScore W79901769C71924100 @default.
• W79901769 hasConceptScore W79901769C90924648 @default.
• W79901769 hasIssue "3" @default.
• W79901769 hasLocation W799017691 @default.
• W79901769 hasLocation W799017692 @default.
• W79901769 hasOpenAccess W79901769 @default.
• W79901769 hasPrimaryLocation W799017691 @default.
• W79901769 hasRelatedWork W1997375495 @default.
• W79901769 hasRelatedWork W2015993259 @default.
• W79901769 hasRelatedWork W2095714646 @default.
• W79901769 hasRelatedWork W2110354542 @default.
• W79901769 hasRelatedWork W2140569101 @default.
• W79901769 hasRelatedWork W2161159725 @default.
• W79901769 hasRelatedWork W230393467 @default.
• W79901769 hasRelatedWork W2407584233 @default.
• W79901769 hasRelatedWork W3165192063 @default.
• W79901769 hasRelatedWork W79901769 @default.
• W79901769 hasVolume "23" @default.
• W79901769 isParatext "false" @default.
• W79901769 isRetracted "false" @default.
• W79901769 magId "79901769" @default.
• W79901769 workType "article" @default.